Lin B, Kennedy B, McBride J, et al. - In children with acute lymphoblastic leukemia (ALL), researchers assessed the long-term pulmonary morbidity of respiratory viral infections (RVIs) during chemotherapy. Participants in the study were childhood ALL survivors (aged 7 to 18 years) greater than 6 months posttreatment. Criteria for exclusion involved hematopoietic stem cell transplant (HSCT) or proven bacterial/fungal respiratory infection during treatment. The study sample consisted of 54 patients (31 viral, 23 control). According to findings, RVIs children during chemotherapy developed more long-term respiratory symptoms, especially wheeze and cough compared with controls. However, differences did not reach statistical significance. Between the two groups, no differences in static lung function were found. Overall, almost a third of ALL survivors treated without HSCT detected pulmonary abnormalities and/or significant ongoing respiratory symptoms. For evaluating the etiology and clinical significance of these results, larger, prospective studies are warranted.